Stories

Aotearoa’s smokefree goal needs policy that matches both ambition and real behaviour. Lower smoking rates will not be secured through slogans alone; they require targeted support, credible enforcement, attention to inequities and realistic alternatives for adults who still smoke. Vaping and other lower-risk options should be assessed by their role in reducing combustion, not by whether they fit an abstinence-only model. Getting back on track means focusing on outcomes: fewer cigarettes, fewer deaths and fewer communities left behind.

Canada’s move to loosen nicotine pouch regulations signals a more practical turn in smoke-free policy. Keeping pouches behind excessive barriers can limit oversight, reduce adult access and leave smokers with fewer alternatives to cigarettes. A better framework would combine age controls, product standards and clear risk communication with legal routes that adults can realistically use. Regulation should make lower-risk products accountable, not invisible.

Oral nicotine products should not be treated as a single risk category. Snus, nicotine pouches, chewing tobacco and traditional oral products can differ widely in ingredients, processing, contaminants and patterns of use. Those differences matter because public health guidance should help consumers and regulators understand where risk is actually concentrated. A clearer risk hierarchy can support better choices, stronger standards and more credible harm reduction policy.

Illicit tobacco is what happens after policy stops accounting for demand. High taxes, restricted safer alternatives and confidence in top-down control can turn nicotine into a market run less by retailers and more by criminal networks. That weakens age checks, product standards and public oversight while keeping cigarettes cheap for those willing to buy outside the law. The lesson is uncomfortable but clear: reducing harm requires legal pathways that work better than the illicit ones.

FDA e-cigarette authorisation should be a scientific process, not a political obstacle course. Adult smokers need legal products assessed on evidence, exposure and their potential to reduce harm compared with continued smoking. A system that delays or rejects lower-risk options while cigarettes remain widely available sends the wrong signal. Regulation should protect consumers without allowing politics to decide which routes away from combustion survive.

The EU’s delayed tobacco tax vote shows how contested the future of nicotine policy has become. Sweden’s election has turned timing into strategy, but the deeper question is whether Europe will tax according to risk or flatten cigarettes, vapes, pouches and heated tobacco into one category. A credible fiscal framework should keep combustible tobacco clearly less attractive than lower-risk alternatives. Tax policy can raise revenue, but it should not erase the incentives that help smokers move away from combustion.

The UK vaping duty risks weakening one of the clearest incentives for smokers to switch. Price signals matter: legal vapes need to remain more attractive than cigarettes and safer than the illicit market. A tax designed to raise revenue can still create public health costs when it makes lower-risk products harder to afford. Tobacco policy should discourage smoking without punishing the people who have already moved away from combustion.

Harm reduction feels different for smokers because tobacco control has often treated nicotine use as a moral problem rather than a risk continuum. People who smoke need realistic ways to reduce exposure to the harms of combustion, especially after repeated quit attempts. Safer nicotine products do not remove every risk, but they can change the scale of harm dramatically. Public health should meet smokers with practical options, not only expectations of abstinence.

Australia’s nicotine policy has become a case study in disinformation with real-world consequences. Smokers are told to quit, yet lower-risk alternatives are restricted, misrepresented or pushed into channels with less oversight. That confusion protects cigarettes more than it protects public health. Evidence-based communication should explain relative risk clearly, support adult switching and stop treating harm reduction as a threat to tobacco control.

A patient who still smokes is not a failure of character. It may be a sign that the advice, tools or assumptions around quitting are not meeting the reality of dependence. Clinicians can make a difference by asking what has already been tried, what keeps the cigarette in place, and whether lower-risk nicotine options could support a move away from combustion. Smoking cessation works better when care starts with the person, not the expectation that one method should work for everyone.